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The ability to cure hepatitis C virus (HCV) infection, a chronic infectious disease, with all-
oral interferon-free direct-acting antiviral (DAA) therapies has brought considerable energy to 
the HCV sector. WHO has set an ambitious goal to eliminate HCV as a major public health 
threat by 2030 (WHO, 2017a). This is a goal certainly worth striving for, but it will take a 
massive investment to enhance HCV prevention, awareness, linkage of people with HCV to 
testing, care and treatment. Also, given the burden of HCV in people who inject drugs 
(PWID), they will need to be key partners and a priority population for this endeavour to be 
successful globally.  
 
This special issue published in the International Journal of Drug Policy includes original 
research articles, systematic and expert reviews, and commentaries focused on the 
“Elimination of hepatitis C virus infection among PWID: The beginning of a new era of 
interferon-free DAA therapy”. Following a call for abstracts, these articles were received and 
guest-edited in collaboration with members from the International Network on Hepatitis in 
Substance Users (INHSU), an international organization dedicated to scientific knowledge 
exchange, knowledge dissemination, education, and advocacy focused on improving HCV 
prevention and care among PWID. This guest-edited special issue focuses on HCV among 
PWID and addresses: epidemiology and prevention; the cascade of HCV care; strategies to 
enhance testing, linkage to care, and treatment uptake; and HCV treatment, with a focus on 
real-world data on the efficacy of interferon-free DAA therapy. This issue also includes a set 
of research priorities to achieve universal access to HCV prevention, management and direct-
acting antiviral treatment among PWID (Grebely et al. THIS ISSUE).  
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Epidemiology and prevention of HCV infection among PWID 
PWID include those who have injected an illicit drug at least once in their life. This 
population consists of both former injectors having ceased injecting and “recent” injectors 
(with definitions for “recent” varying in the literature from one month to one year). Among 
people with a history of injecting, a population of people receiving opioid substitution therapy 
(OST) for opioid dependence also exists, some of whom may continue to inject drugs 
(Larney, et al., 2015). 
 
Globally, among the 71 million people infected with HCV, there is a large burden of HCV 
infection among recent PWID, with a 50% prevalence of chronic infection (Nelson, et al., 
2011; WHO, 2017b), representing an estimated 5.6 million PWID with chronic HCV 
infection (8% of all infections globally) (Nelson, et al., 2011; WHO, 2017b). There is also a 
large, but unquantified, number of chronic HCV infections among PWID who have ceased 
injecting (B. Hajarizadeh, Grebely, & Dore, 2013; Nelson, et al., 2011). Morbidity and 
mortality due to HCV infection continues to rise among recent and former PWID (B. 
Hajarizadeh, et al., 2013; Stanaway, et al., 2016). 
 
In 2015, there were 1.7 million new HCV infections globally, with 23% attributable to current 
injecting drug use (WHO, 2017b), related to the high HCV incidence among PWID in many 
settings (Hagan, Pouget, Des Jarlais, & Lelutiu-Weinberger, 2008; Morris, et al., 2017; Page, 
Morris, Hahn, Maher, & Prins, 2013; Wiessing, et al., 2014), particularly in the initial years of 
injecting (Hagan, et al., 2008; Roy, Boudreau, & Boivin, 2009), and in key vulnerable 
populations.  
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Aboriginal PWID are disproportionally affected by HCV in many countries (Graham, Harrod, 
Iversen, & Simone Hocking, 2016; Lelutiu-Weinberger, et al., 2009; Miller, et al., 2002). In 
this issue, Graham et al. evaluate trends in HCV antibody prevalence among Aboriginal and 
Torres Strait Islander people attending Australian needle and syringe programmes (NSP) 
between 1996 and 2015 (Graham et al THIS ISSUE). Among 16,948 PWID, 11% identified 
as Aboriginal, with the proportion of Aboriginal respondents increasing from 7% in 1996-
2000 to 16% in 2011-2015. While the reason for this increase in proportion of Aboriginal 
respondents is unclear, this is a concern if it represents an increase in the Aboriginal PWID 
population as compared to the number of Aboriginal PWID accessing NSP services. The 
HCV antibody prevalence was higher among Aboriginal PWID (60%), compared to non-
Aboriginal PWID (52%, P<0.001). Also, injecting risk behaviours remained consistently high 
among Aboriginal PWID with no change over the last two decades, compared to a decrease 
observed among non-Aboriginal PWID. This study clearly demonstrates that further work is 
needed to develop improve culturally appropriate education and health promotion about safer 
injecting practices among Aboriginal PWID to prevent HCV infection. 
 
Prescription opioid injecting has been associated with increased incidence (Bruneau, Roy, 
Arruda, Zang, & Jutras-Aswad, 2012) and prevalence of HCV infection (Hadland, et al., 
2014; Havens, et al., 2013; Havens, Walker, & Leukefeld, 2007; Zibbell, Hart-Malloy, Barry, 
Fan, & Flanigan, 2014). The injecting of prescription opioids has increased considerably over 
the past two decades in North America (Fischer & Argento, 2012; Jordan, Blackburn, Des 
Jarlais, & Hagan, 2017; B. D. Marshall, Green, Yedinak, & Hadland, 2016) and 
internationally (B. D. Marshall, et al., 2016). This is a major concern with respect to HCV 
prevention efforts. Many prescription opioid users are also poly-drug users; an evidenced 
barrier to opioid substitution therapy (OST) access (Strike, Millson, Hopkins, & Smith, 2013). 
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In this issue, Puzhko et al. examined the association between specific drugs and number of 
drugs used in addition to injected prescription opioids, and HCV seroconversion in a cohort 
study of HCV seronegative PWID in Montreal (Puzhko et al. THIS ISSUE). Among 356 
participants, 35% reported injecting prescription opioids in the past month at enrolment. The 
relative excess risk was highest for co-use of injecting prescription opioids with injecting 
cocaine, smoked/crack cocaine, and non-injected tranquilizers. Higher risk was also observed 
with increasing the number of these three drugs used in combination with prescription 
opioids. These findings suggest that poly-drug use among people who inject prescription 
opioids must be addressed to reduce HCV transmission.   
 
The cascade of HCV care among PWID 
The cascade of HCV care has been modified from initial applications in the field of HIV 
(Gardner, McLees, Steiner, Del Rio, & Burman, 2011). In the setting of HCV, it often 
includes those tested and diagnosed, linked to care, initiating treatment and achieving a 
successful treatment outcome (Behzad Hajarizadeh, Grebely, Matthews, Martinello, & Dore, 
2016; Yehia, Schranz, Umscheid, & Lo Re, 2014).  Cascades of care provide a framework for 
monitoring population-level clinical and public health outcomes, identify gaps in the 
continuum of care, and provide insight into potential opportunities for intervention.  
 
There have been few studies evaluating the HCV cascade of care among PWID. In this issue, 
Iversen et al. estimated the cascade of HCV testing, care and treatment among PWID prior to 
the introduction of broadly accessible DAA therapies in Australia (Iversen THIS ISSUE). 
Among the estimated 93,000 PWID in Australia, 89% had a history of HCV antibody testing, 
with 57% testing positive for HCV antibodies and less than half (46%) of HCV antibody 
positive people having received confirmatory HCV RNA testing. Among the estimated 
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43,201 PWID with active HCV infection or chronic infection that had been successfully 
treated, 31% had received specialist HCV assessment, 8% had received antiviral treatment 
and 3% were cured.  
 
This is consistent with another article in this issue by Butler et al. from a different national 
sample (n=888) of PWID in Australia demonstrating that 93% reported a history of HCV 
antibody testing, with only 60% having confirmatory testing (Butler THIS ISSUE). Among 
participants who reported a positive result (n=435), 54% identified their regular general 
practitioner as the setting where their most recent antibody test was conducted. These findings 
highlight the importance of further work to enhance education and training about HCV testing 
among general providers to ensure that people receive testing for active infection (HCV RNA) 
following testing for previous exposure (HCV antibody) or the development of new 
technologies to obviate the need for a second test such as reflex testing or point of care RNA 
tests (J. Grebely, F. M. J. Lamoury, et al., 2017; Hirsch, et al., 2014). 
 
In a cohort of rural PWID in Kentucky, Stephens et al. demonstrated that despite 59% of 
participants reporting having contact with a healthcare provider within 18 months of a 
detectable test for HCV infection and counselling, only 14% reported seeking HCV treatment 
and only 8% reported receiving treatment (Stephens et al. THIS ISSUE). Having health 
insurance, internet access, and prior treatment for substance use increased the odds of making 
contact for follow-up, while major depressive disorder and prior methadone use (either legal 
or illegal) were associated with decreased likelihood. Clearly, novel strategies to support 
integrated services among those already accessing services are needed to improve the 
proportion of people engaging in HCV care are needed, particularly in rural settings. 
Considerable barriers to accessing DAA therapies due to reimbursement restrictions based on 
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fibrosis stage, recent drug/alcohol use, and provider type also remain in the United States, 
which further restrict access (Barua, et al., 2015; Ooka, Connolly, & Lim, 2017). 
 
In some countries, such as the Netherlands, access and reimbursement for DAA therapy 
occurred earlier (since 2014) than many other settings. Van Santen et al. evaluated HCV 
treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies 
between 1985 and 2015 (Van Santen et al. THIS ISSUE). Among 1,305 people who use 
drugs, 20% were HIV antibody positive and 62% were HCV antibody positive at study entry. 
In contrast to the studies by Iversen and Butler, 95% of HCV antibody positive individual 
received HCV RNA testing, partly related to the well-characterized nature of this cohort. The 
proportion of people receiving HIV antiretroviral therapy increased from 5.7 in 1990, and 
42.2% in 1996, to 91.7% in 2015. HCV-treatment coverage increased from 7% in 2005 to 
44% in 2015. The highest proportion of people who use drugs initiating HCV treatment 
(9.7%) was observed in 2006, but this decreased to 1.9% in 2013. During 2015, the first full 
year of DAA availability, HCV treatment initiation remained low (3%, 1 of 33 people who 
were HCV RNA positive).  Of those with available Fibroscan results in 2015, 58% had no or 
mild fibrosis (F0-F1). As such, the lower treatment uptake was likely related to the fact that 
until November 2015, access to HCV treatment was restricted, based on fibrosis stage 
(Metavir >=F3), so physicians may have awaited the dismissal of such restriction.  
 
 
This is consistent with a recent study of DAA restrictions in Europe demonstrating that DAA 
reimbursement was restricted to ≥F2 in 57% of countries, required a specialist prescriber in 
97% of countries, and required abstinence of substance use prior to treatment in 14% of 
countries (A. D. Marshall, et al., 2017). As raised by a study by Lazarus et al. in this issue 
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(Lazarus THIS ISSUE), the barriers based on drug and alcohol use in practice are probably 
much greater, given perceptions by some providers about poor adherence, lower response to 
therapy, and the risk of reinfection may preclude successful treatment (Asher, et al., 2016; 
Grebely & Tyndall, 2011). Many physicians are also unwilling to treat people actively using 
drugs with DAA therapies. In a 2016 study of HCV practitioners in the DAA era (72% were 
gastroenterology and hepatology specialists), only 15% were willing to treat people who are 
actively injecting drugs with all-oral regimens (Asher, et al., 2016). Reinfection, adherence 
and medication cost were cited as the most important concerns when determining candidacy 
(Asher, et al., 2016). Further work is needed to improve education and training for providers, 
particularly with respect to information about successful HCV treatment outcomes and low 
rates of reinfection among recent PWID and strategies for reducing stigma and discrimination. 
Indeed, as other barriers (such as concerns about efficacy and side-effects) diminish, the 
importance of stigma and discrimination as barriers to HCV treatment may increase (Brener, 
Horwitz, von Hippel, Bryant, & Treloar, 2015). Also, as highlighted by Lazarus et al. further 
work is needed to drive policy change to remove the restrictions place for DAA therapy 
reimbursement and community-based patient organizations will be a key stakeholder in 
moving this agenda forward (Lazarus THIS ISSUE).    
 
Enhancing testing, linkage to care, and treatment for PWID 
Reducing the burden of HCV infection among PWID will require targeted strategies focused 
on different stages of the HCV cascade of care. In this issue, Bajis et al. performed a 
systematic review to evaluate the effectiveness of interventions to enhance HCV testing, 
linkage to care, and treatment uptake among PWID (Bajis THIS ISSUE). Among 10,116 
records identified, a total of 14 studies were included, of which 57% were randomised 
controlled trials. Interventions to enhance HCV testing included on-site testing with pre-test 
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counselling and education (Cullen, et al., 2006; Hagedorn, et al., 2007; Lacey, Ellen, Devlin, 
Wright, & Mijch, 2007; Merchant, et al., 2014; Merchant, DeLong, Liu, & Baird, 2015; 
Rosenberg, et al., 2010; Roux, et al., 2016); and dried blood spot testing (Hickman, et al., 
2008; Radley, et al., 2017). Interventions to enhance linkage to care included facilitated 
referral for HCV assessment and scheduling of specialist appointments for clients (Cullen, et 
al., 2006; Masson, et al., 2013; Tait, McIntyre, McLeod, Nathwani, & Dillon, 2010). 
Interventions to enhance HCV treatment uptake included integrated HCV care, drug use and 
psychiatric services delivered by a multidisciplinary team with case management services, 
with or without non-invasive liver disease assessment (Ho, et al., 2015; Moussalli, et al., 
2010). All studies were conducted in the interferon treatment era and there were no studies 
conducted in low- and middle-income countries. Although a number of other strategies were 
assessed, they lacked a comparator group, so measuring the effect of these interventions was 
difficult. This study highlights that further data is needed to identify strategies to enhance 
HCV testing, linkage to care, and treatment in the DAA era to strive towards HCV 
elimination among PWID. 
 
Mathematical modelling suggests that HCV treatment as prevention (modest scale-up of DAA 
HCV treatment to 8 per 100 PWID) could lead to substantial reductions in HCV prevalence 
among PWID, thereby lowering HCV incidence and preventing transmission (de Vos, Prins, 
& Kretzschmar, 2015; European Union, 2017; Hellard, et al., 2014; Lima, et al., 2015; Martin, 
Hickman, Hutchinson, Goldberg, & Vickerman, 2013; Martin, et al., 2011; Martin, 
Vickerman, et al., 2013; Scott, McBryde, Thompson, Doyle, & Hellard, 2016). In a study by 
Scott et al. in this issue, mathematical modelling was used to assess potential strategies that 
could be used to enhance HCV testing, linkage to care, and treatment to achieve HCV 
elimination targets in Australia, a setting where all people living with HCV have access to 
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DAA therapy (Scott et al. THIS ISSUE). Interventions included point of care HCV RNA 
testing, increased testing of PWID, use of non-invasive biomarkers (e.g. AST to platelet ratio 
index, APRI) in place of liver stiffness measurements, and scaling up treatment delivery in 
primary care. Without additional health systems interventions, the projected increase in DAA 
treatment had a substantial impact on reducing the number of people living with HCV by 
2030. However, most remaining infections were undiagnosed and occurred among PWID. 
The scale-up of primary care delivery and use of biomarkers in place of liver stiffness 
measurement produced modest impacts on HCV transmission, but saved AU$32 million by 
2030. Additional screening of PWID was required to achieve HCV elimination targets, and 
the addition of point of care RNA testing increased the healthcare cost savings to AU$62 
million. This study provides important data to highlight that even with unlimited and 
unrestricted access to HCV DAA treatment, interventions to improve the HCV cascade of 
care and address HCV among PWID will be required to achieve elimination targets. 
 
Enhancing HCV case finding is one strategy that could be used to enhance HCV testing. In 
the Netherlands, Helsper et al. evaluated effectiveness and cost-effectiveness of a nationwide 
HCV case finding campaign aimed at drug users (individual counseling and testing at drug 
treatment centres) and high-risk people in the general population (health education through 
mass-media and education of health care professionals) as part of a national non-randomized 
controlled trial (Helsper THIS ISSUE). The intervention targeted towards PWID identified 
257 additional people with HCV and was cost-effective (ICER was €9,056 compared to no 
intervention), while the intervention targeted towards the general population identified 38 
additional people with HCV and was less cost-effective (ICER was €18,421 compared to no 
intervention). Further studies are needed to evaluate the cost-effectiveness of strategies to 
improve HCV testing among PWID.  
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Pharmacies may also present an interesting setting to enhance HCV testing and treatment. In a 
study from Scotland, Radley et al performed an exploratory cluster randomised controlled 
trial with mixed methods evaluation to compare the uptake of dried blood spot testing and 
treatment of people with HCV genotype 1 infection in a conventional service pathway versus 
a pharmacist-led pathway in a population receiving OST (Radley THIS ISSUE). Participants 
in the pharmacist-led pathway were more likely to take a dried blood spot test (36% vs. 24%, 
P=0.003) and attend for subsequent assessment (77% vs. 27%, P=0.002). This study provides 
interesting preliminary data to suggest that pharmacy-based testing, assessment, and treatment 
could be a feasible model of HCV care to explore in future studies.  
 
Non-invasive liver disease assessment via transient elastography (e.g. Fibroscan) has also 
been shown to be effective for enhancing liver disease screening and linkage to HCV care 
among PWID attending drug treatment clinics (Foucher, et al., 2009; A. D. Marshall, et al., 
2015; Moessner, et al., 2011). In this issue, Marshall et al evaluated the decisions and 
experiences of people having received a liver disease assessment as part of a liver health 
education and promotion campaign, including interpretation of their transient elastography 
score and subsequent health behaviours, using a health literacy framework (Marshall THIS 
ISSUE). Among the participants interviewed, most participants interpreted their level of liver 
disease correctly based on their transient elastography score. Participants with higher transient 
elastography scores frequently described feeling surprised by their result and, often 
incorrectly identified drug use as a cause of advanced liver disease. In contrast, persons with 
lower transient elastography scores felt encouraged by their result and spoke more to 
maintenance of healthy behaviours. Findings highlight some positive health changes made by 
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PWID following liver disease assessment as well as ongoing misunderstandings of chronic 
liver disease in relation to illicit drug use.  
 
Among PWID, despite a high willingness to receive HCV therapy, poor knowledge about 
HCV testing, factors which influence liver disease progression, and the chance of cure with 
new HCV treatments has been observed (A. D. Marshall, et al., 2015; Treloar, et al., 2011; 
Treloar, Hull, Dore, & Grebely, 2012). In this issue, Mah et al evaluated factors associated 
with HCV knowledge and treatment willingness among PWID in Vancouver, Canada in the 
era of DAA therapy (Mah et al. THIS ISSUE). Among 630 participants, the mean scores for 
HCV knowledge and treatment willingness were high, with mean composite scores of 25 out 
of 30, and 6.8 out of 10, respectively. Overall, 61% strongly agreed or agreed to consider 
starting HCV treatment in the next year. Interestingly, when asked if they prioritized 
treatment duration versus risk of side effects, 58% reported risk of side effects as a more 
important treatment consideration while only 16% were more concerned about treatment 
duration. Also, 57% of participants reported that what they have heard about the side effects 
of HCV treatment scares them. Further, only 66% answered “agree” or “strongly agree” to the 
question “Treatment for hepatitis C can cure the infection in most people”, with 51% still 
believing that HCV treatment included a weekly interferon injection. This clearly indicates 
the need to improve knowledge and address patient perceptions that are influenced by the 
‘horror stories’ of negative experiences of liver biopsies and HCV treatment propagated 
within peer networks in the interferon-era (Swan, et al., 2010). Overall, among 630 
participants, 53% reported having ever been offered HCV treatment and of those offered 
therapy, only 9% ever initiated treatment. A greater degree of HCV knowledge was associated 
with an increased willingness to pursue HCV treatment. These data suggest that strategies to 
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increase HCV knowledge among PWID may be an integral component for enhancing the 
HCV cascade of care.  
 
Novel strategies to improve knowledge about HCV among PWID are needed. In a study of 
people attending OST and NSP services in Malaysia, Mukherjee et al. evaluated a 
standardized, 45-minute HCV education program to measure change in knowledge and 
treatment willingness (Mukherjee THIS ISSUE). Baseline knowledge was consistently low 
across OST and NSP clients. More specifically, most OST clients were unaware that HCV 
often has no symptoms, sterilizing used needles often does not kill HCV, re-infection is 
possible, that HCV treatment is not always effective, and that treatment is not life-long. Most 
NSP clients seemed to be unaware that HCV is a virus that affects the liver (18%). Following 
the short educational intervention, knowledge scores and treatment interest among people 
receiving OST increased by 68% and 16%, respectively (p<0.001), although similar 
improvements were not observed in people in NSP. Integrating a brief, but comprehensive 
HCV education session may be a low-cost and effective strategy to improve HCV knowledge. 
However, further work is needed to evaluate whether the improvements in knowledge are 
sustained long-term. Further work is needed to develop education and health promotion 
initiatives to improve knowledge among PWID with HCV. This will be a crucial component 
to enhance engagement in HCV care among PWID moving forward.  
 
HCV treatment for PWID 
Although interferon-based HCV therapy is safe and effective among PWID (Aspinall, et al., 
2013; Dimova, et al., 2013; Hellard, Sacks-Davis, & Gold, 2009), patient, provider, health 
system, structural, and societal barriers (Grebely, Oser, Taylor, & Dore, 2013; Harris & 
Rhodes, 2013; Wolfe, et al., 2015) have led to low diagnosis and treatment for HCV infection 
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in the interferon-era (Alavi, et al., 2014; Iversen, et al., 2014). The availability of tolerable 
and simple direct-acting antiviral (DAA) therapies for HCV infection with cure rates >95% 
represents one of the greatest medical advances in decades (Dore & Feld, 2015; Falade-
Nwulia, et al., 2017). New DAA therapies have overcome many barriers associated with 
interferon-based therapy for PWID as they have fewer psychiatric side effects, are simpler 
(oral, once-daily vs. weekly injections), and shorter in duration (8-12 weeks vs. 24-48 weeks). 
 
Treatment of HCV infection among PWID provides benefits at the population level and the 
individual level. At a population level, treatment of HCV in PWID with ongoing injecting 
drug use represents a potential tool to prevent onward HCV transmission among PWID 
(Martin, Vickerman, et al., 2013). Mathematical modelling also indicates that DAA treatment 
of PWID is cost-effective, given the prevention benefit (Martin, et al., 2016). At an individual 
level, successful treatment of HCV infection improves health-related quality of life (Younossi 
& Henry, 2015), reduces the progression of liver disease (Grebely & Dore, 2011) and reduces 
all-cause mortality in people with advanced liver disease (van der Meer, et al., 2014). 
International guidelines also support the prioritization of HCV treatment among PWID 
(AASLD/IDSA, 2015; European Association for Study of, 2015; Grebely, et al., 2015; WHO, 
2014).  
 
Globally, DAA availability is uneven; with many countries restricting access to contain costs 
(Barua, et al., 2015; A. D. Marshall, et al., 2017; A. D. Marshall, et al., 2016). DAA 
prioritisation can negatively impact access for PWID, particularly if it is based on disease 
staging criteria. Harris et al examined and critiqued HCV prioritisation discourses based on 
clinical and population-based markers, with reference to the social and individual-level 
treatment benefits experienced by her UK participants (Harris, et al. IJDP THIS ISSUE). In 
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this issue, she reports findings from a longitudinal qualitative study following participants 
through HCV treatment in the UK. Data were collected during a time of transition to DAAs; 
many participants were offered triple therapy comprising interferon, ribavirin and a first-
generation protease inhibitor. Despite the forthcoming availability of less toxic DAA 
treatments, all but one participant chose to commence treatment immediately. Reasons for 
commencing treatment related to expectations and hopes for reconnection with loved ones 
and the broader community; through removal of HCV stigma, symptoms and transmission 
fears. Longitudinal methods enabled investigation of how expectations mapped to outcomes; 
for many these HCV treatment benefits were realised. This work is important in that it 
evidences patient-reported HCV treatment benefits beyond the clinical; crucial to account for 
in contexts of restricted access but also to harness in the design of HCV treatment 
engagement interventions for PWID.  
 
Interferon-based therapy is safe and effective among PWID (Aspinall, et al., 2013; Dimova, 
et al., 2013; Hellard, et al., 2009). In this issue, Grebely et al. present the results from the first 
international clinical trial from the ACTIVATE Network, which was a trial to evaluate 
response-guided interferon-based HCV therapy for participants with HCV genotypes 2/3 and 
recent injecting (previous 6 months) or receiving OST, prior to the availability of DAA 
therapy between 2012 and 2014 (Grebely THIS ISSUE). Participants received open-label 
directly observed peg-interferon alfa-2b and self-administered ribavirin for 12 (for those 
HCV RNA undetectable at week 4) or 24 weeks (for those HCV RNA detectable at week 4). 
Overall, 76% completed treatment, with higher treatment completion observed among those 
receiving 12 vs. 24 weeks of treatment (97% vs. 46%, P < 0.001) (Cunningham, et al., 2017). 
SVR12 was 66% overall, and 84% in those with undetectable HCV RNA at week 4 (12 
weeks) compared to 38% in those without (24 weeks). In adjusted analysis, cirrhosis vs. 
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no/mild fibrosis [adjusted OR (aOR) 0.33, 95% CI 0.13, 0.86] predicted reduced SVR12, 
while response at week 4 was associated with increased SVR12 [aOR 8.11, 95% CI 2.73, 
24.10]. Recent injecting drug use at baseline or during therapy was not associated with SVR.  
 
Previous studies have demonstrated that reductions in injecting risk behaviours may occur in 
the setting of interferon-based treatment (Alavi, et al., 2015). In another paper from the 
ACTIVATE study, Midgard et al. evaluated trends in injecting drug use risk behaviours 
during and following HCV treatment (Midgard THIS ISSUE). Overall, recent injecting drug 
use and hazardous alcohol use decreased, while OST increased during and following HCV 
treatment among participants with ongoing injecting drug use. This is consistent with another 
paper in this issue by Artenie et al. which examined changes in injecting drug use among 
PWID treated for acute HCV infection (Artenie et al. THIS ISSUE). In multivariate analyses 
adjusting for age, gender and injection drug use at baseline, those who received interferon-
based treatment [Adjusted odds ratio (AOR): 0.18; 95% Confidence interval (CI): 0.04-0.76], 
those who had spontaneously cleared infection (AOR: 0.34; 95% CI: 0.08-1.40), and those 
with contraindications to therapy (AOR: 0.24; 95% CI: 0.05-1.22) were less likely to report 
injection drug use at follow-up relative to those who chose not to engage in HCV care post-
diagnosis. These findings may be attributed to ongoing therapeutic relationships and harm 
reduction education provided by physicians, nurses, counsellors and other allied health 
provides to patients may contribute to reductions in injecting risk behaviours. This illustrates 
the important role that health care in the context of HCV care can play to improve drug user 
health, more broadly. Further research is needed to understand whether similar reductions in 
injecting risk behaviours are observed in the setting of DAA therapy, where contact with 
healthcare providers is sometimes less frequent.  
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DAA therapy has improved the feasibility of HCV treatment among PWID compared to 
interferon-based therapies, given DAA therapies have limited psychiatric side effects, are 
simpler (oral, once-daily vs. weekly injections), and shorter in duration (8-12 weeks vs. 24-48 
weeks). Among people receiving OST with no recent illicit drug use, post-hoc analyses of 
phase 2 and 3 trials of DAA therapy have demonstrated that the SVR is similar in those 
receiving and not receiving OST (G. J. Dore, et al., 2016; Feld, et al., 2014; Grebely, Dore, et 
al., 2016; J. Grebely, I. M. Jacobson, et al., 2017; Grebely, Mauss, et al., 2016; J.  Grebely, et 
al., 2017; Puoti, et al., 2014; Zeuzem, et al., 2015). However, the majority of these trials 
excluded people with active drug use from participation. The first phase 3 trial to evaluate 
DAA therapy in people receiving OST including those with ongoing drug use was the C-
EDGE CO-STAR study (G. J.  Dore, et al., 2016). Overall, among people with no previous 
treatment experience and HCV genotypes 1, 4, or 6 and stable methadone or buprenorphine 
(with or without naloxone) who received elbasvir and grazoprevir for 12 weeks (n=296), 
treatment completion was 96%, 97% demonstrated >95% adherence, and the overall SVR 
was 91%.  
 
This issue contributes substantially to the literature to provide additional data on the efficacy 
of DAAs among PWID treated in the real-world. In studies from Australia (Read et al. THIS 
ISSUE, Morris et al. THIS ISSUE), Canada (Mason et al. THIS ISSUE), the Ukraine 
(Mazhnaya et al. THIS ISSUE), and the United States (Norton et al. THIS ISSUE) among 
people with a history of injecting drug use (with and without recent drug use) an overall 
treatment completion of 93-100% and SVR of 80-96% was observed. Although some studies 
demonstrated lower SVR in intent-to-treat analyses than observed in phase 3 clinical trials, 
the majority of non-response occurred as a result of lost to follow-up between ETR and 
SVR12 and not virological failure or relapse (Read et al. THIS ISSUE, Morris et al. THIS 
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ISSUE, Mason et al. THIS ISSUE, Mazhnaya et al. THIS ISSUE). In modified intent-to-treat 
analyses excluding individuals lost to follow-up between ETR and SVR, SVR12 of 91-94% 
was observed (Read et al. THIS ISSUE, Morris et al. THIS ISSUE, Mason et al. THIS 
ISSUE, Mazhnaya et al. THIS ISSUE). These data suggest that the period between ETR and 
SVR12 is an important time for maintaining engagement in post-treatment care and follow-
up. Importantly, drug use prior to or during therapy does not have an impact on SVR (Read et 
al. THIS ISSUE, Morris et al. THIS ISSUE, Mason et al. THIS ISSUE, Mazhnaya et al. 
THIS ISSUE, Norton et al. THIS ISSUE). However, study populations do vary with respect 
to the proportion with recent drug use or injecting drug use, the definitions used to define 
recent drug use (vary from 1-12 months), and some studies do not report information on 
recent drug use. In the future, studies of DAA treatment in PWID should collect standardized 
information about injecting risk behaviours and this information should be reported.  
 
Among people with recent injecting drug use, there are now several studies evaluating 
outcomes following DAA therapy. In a study of 174 participants with injecting drug use in 
the last year (63% with cirrhosis, 37% with previous treatment experience, 58% genotype 1), 
95% completed therapy and 93% achieved SVR (Boglione, et al., 2017). The SIMPLIFY 
study was the first international trial that evaluated DAA therapy in people with recent 
injecting drug use (J. Grebely, O. Dalgard, et al., 2017). Overall, among people with HCV 
genotypes 1-6 treated with sofosbuvir and velpatasvir for 12 weeks (n=103), 96% completed 
treatment and 94% had an SVR, with no virological failures, and one reinfection. These data 
provide strong support for DAA treatment among people with recent injecting drug use.  
 
OST also provides an important opportunity to engage HCV-positive PWID into DAA-based 
therapy. In this issue, Panagiotoglou et al. used well-characterized data from cohorts in 
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Vancouver to evaluate whether OST retention could be used to inform DAA therapy 
initiation, thereby identifying opportunities to improve retention (Panagiotoglou et al. THIS 
ISSUE). Overall, among 1,427 participants with HCV/HIV, the odds of subsequent 12-week 
retention in OST was significantly greater in month 3 versus month 1 of OST treatment and 
the odds of subsequent 8-week retention in OST was significantly greater in month 2 versus 
month 1. Interestingly, among continuously ART-adherent individuals, the odds of 
subsequent twelve-week retention were not statistically significantly greater in successive 
months, suggesting that those engaged in ongoing HIV care may be ideal for engaging in 
HCV treatment. The authors suggest that this study provides indirect evidence that 12 or 8 
weeks of HCV treatment should be initiated at three months or two months following 
stabilization on OST, respectively. However, this does not take into consideration that HCV 
therapy may provide an opportunity for further engagement in care and positive impact on 
drug dependency management. Also, the authors do not provide direct evidence to suggest 
that people who are stabilized on OST before initiating DAA therapy have higher responses 
to therapy, particularly given the high responses observed with DAA therapy among recent 
PWID to date (Boglione, et al., 2017; J. Grebely, O. Dalgard, et al., 2017). 
 
There is good evidence to support that involving community-based PWID organizations in 
the design and implementation of programs can reduce stigma and discrimination, enhance 
HCV and HIV prevention and care, and lead to changes in health policies (United Nations 
Office on Drugs and Crime, 2017). Peer-based support and involvement is recognized as a 
vital component to facilitate HCV testing and treatment and a number of different models 
have been described (Crawford & Bath, 2013; Treloar, et al., 2015). In this issue, Bonnington 
and Harris explore peer education and buddy support as part of an intervention to enhance 
HCV diagnosis and treatment in primary care and drug treatment settings between 2014 and 
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2016 (Bonnington and Harris THIS ISSUE). Participants had common expectations of the 
peer role (to 'just be there') and its occupants' attributes (empathy, trustworthy, etc.). 
However, in practice, peers faced constraints on realising these expectations. A 'recovery' 
dominated drug treatment ethos in the UK appeared to influence the selection of 'recovery 
champions' as peers for the intervention. This created tensions in relations with clients, 
particularly when risk-adverse discourses were internalised by the peers. Peers were poorly 
integrated and supported within the service, affecting opportunities to relate and build trust 
with clients. Thus, the scope for peer support to impact on the nature and extent of clients' 
testing and treatment for HCV was limited. This paper highlights that the efficacy of peer 
involvement can be constrained by organisational structures and boundaries - especially 
regarding who is deemed to be 'a peer'. Peer programmes take time and care to implement 
and weave into wider recovery and harm reduction frameworks. Future research is needed to 
continue to build evidence about the importance of peer-based models of care for PWID.  
 
Research priorities to achieve universal access to hepatitis C prevention, management and 
direct-acting antiviral treatment among PWID 
Unfortunately, there remain gaps in knowledge that represent barriers to effective prevention 
and management of HCV among PWID. As part of this special issue, Grebely et al. present 
the outcomes of an expert round table panel to assess current research gaps and establish 
future research priorities for the prevention and management of HCV among PWID led by 
The Kirby Institute, UNSW Sydney and the International Network on Hepatitis in Substance 
Users (INHSU) (Grebely et al. THIS ISSUE). This round table consisted of a one-day 
workshop held on 6 September, 2016, in Oslo, Norway, prior to the International Symposium 
on Hepatitis in Substance Users (INHSU 2016). International experts in drug and alcohol, 
infectious diseases, and hepatology were brought together to discuss the available scientific 
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evidence, gaps in research, and develop research priorities. Topics for discussion included the 
epidemiology of injecting drug use, HCV, and HIV among PWID, HCV prevention, HCV 
testing, linkage to HCV care and treatment, DAA treatment for HCV infection, and 
reinfection following successful treatment. This paper highlights the outcomes of the 
roundtable discussion focused on future research priorities for enhancing HCV prevention, 
testing, linkage to care and DAA treatment for PWID as we strive for global elimination of 
HCV infection. 
 
Conclusions  
As we move towards the WHO targets to eliminate HCV infection as a global public health 
concern by 2030, PWID will be a key priority population for efforts to enhance prevention, 
increase diagnosis and treatment and reduce morbidity and mortality. This special issue 
contributes important data to the literature to help further guide efforts to enhance HCV 
prevention, linkage to care, and treatment for PWID. Although interferon-free DAA therapies 
provide us with important tools to achieve the WHO goals, there is still a considerable way to 
go with respect to improving the coverage of strategies to prevent HCV among PWID (e.g. 
OST and NSP), enhancing testing and diagnosis, and broadening access to DAA therapies to 
facilitate HCV elimination efforts among PWID. As we move forward, efforts should focus 
not only on improving care for HCV infection, but also improving the overall health of 
PWID. 
 
 
23 
 
References 
AASLD/IDSA. Recommendations for testing, managing, and treating hepatitis C. Retrieved 
January 18 2015 from www.hcvguidelines.org. 
Alavi, M., Raffa, J. D., Deans, G. D., Lai, C., Krajden, M., Dore, G. J., Tyndall, M. W., & 
Grebely, J. (2014). Continued low uptake of treatment for hepatitis C virus infection 
in a large community-based cohort of inner city residents. Liver Int, 34, 1198-1206. 
Alavi, M., Spelman, T., Matthews, G. V., Haber, P. S., Day, C., van Beek, I., Walsh, N., 
Yeung, B., Bruneau, J., Petoumenos, K., Dolan, K., Kaldor, J. M., Dore, G. J., 
Hellard, M., Grebely, J., & Group, A. S. (2015). Injecting risk behaviours following 
treatment for hepatitis C virus infection among people who inject drugs: The 
Australian Trial in Acute Hepatitis C. Int J Drug Policy, 26, 976-983. 
Asher, A. K., Portillo, C. J., Cooper, B. A., Dawson-Rose, C., Vlahov, D., & Page, K. A. 
(2016). Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-
Acting Antiviral Regimens for People Who Inject Drugs. Subst Use Misuse, 51, 1218-
1223. 
Aspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S. J., Dore, G. J., Goldberg, 
D. J., & Hellard, M. E. (2013). Treatment of hepatitis C virus infection among people 
who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect 
Dis, 57 Suppl 2, S80-89. 
Barua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015). 
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of 
Hepatitis C Virus Infection in the United States. Ann Intern Med, 163, 215-223. 
Boglione, L., Mornese Pinna, S., De Nicolo, A., Cusato, J., Cariti, G., Di Perri, G., & 
D'Avolio, A. (2017). Treatment with direct-acting antiviral agents of hepatitis C virus 
infection in injecting drug users: A prospective study. J Viral Hepat. 
Brener, L., Horwitz, R., von Hippel, C., Bryant, J., & Treloar, C. (2015). Discrimination by 
health care workers versus discrimination by others: countervailing forces on HCV 
treatment intentions. Psychol Health Med, 20, 148-153. 
Bruneau, J., Roy, E., Arruda, N., Zang, G., & Jutras-Aswad, D. (2012). The rising prevalence 
of prescription opioid injection and its association with hepatitis C incidence among 
street-drug users. Addiction, 107, 1318-1327. 
Crawford, S., & Bath, N. (2013). Peer support models for people with a history of injecting 
drug use undertaking assessment and treatment for hepatitis C virus infection. Clin 
Infect Dis, 57 Suppl 2, S75-79. 
Cullen, W., Stanley, J., Langton, D., Kelly, Y., Staines, A., & Bury, G. (2006). Hepatitis C 
infection among injecting drug users in general practice: a cluster randomised 
controlled trial of clinical guidelines' implementation. Br J Gen Pract, 56, 848-856. 
Cunningham, E. B., Hajarizadeh, B., Dalgard, O., Amin, J., Hellard, M., Foster, G. R., 
Bruggmann, P., Conway, B., Backmund, M., Robaeys, G., Swan, T., Marks, P. S., 
Quiene, S., Applegate, T. L., Weltman, M., Shaw, D., Dunlop, A., Bruneau, J., 
Midgard, H., Bourgeois, S., Thurnheer, M. C., Dore, G. J., Grebely, J., & Group, A. 
S. (2017). Adherence to response-guided pegylated interferon and ribavirin for people 
who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. 
BMC Infect Dis, 17, 420. 
de Vos, A. S., Prins, M., & Kretzschmar, M. E. (2015). Hepatitis C Virus treatment as 
prevention among injecting drug users: who should we cure first? Addiction. 
Dimova, R. B., Zeremski, M., Jacobson, I. M., Hagan, H., Des Jarlais, D. C., & Talal, A. H. 
(2013). Determinants of hepatitis C virus treatment completion and efficacy in drug 
users assessed by meta-analysis. Clin Infect Dis, 56, 806-816. 
24 
 
Dore, G. J., Altice, F., Litwin, A. H., Dalgard, O., Gane, E. J., Shibolet, O., Luetkemeyer, A., 
Nahass, R., Peng, C., Conway, B., Grebely, J., Howe, A. Y. M., Gendrano, I. N., 
Chen, E., Huang, H., Dutko, F. J. P., Nickle, D. C., Nguyen, B., Wahl, J., Barr, E., 
Robertson, M. N., & Platt, H. L. (2016). Elbasvir/Grazoprevir to Treat HCV Infection 
in Persons Receiving Opioid Agonist Therapy: A Randomized Controlled Trial (C-
EDGE CO-STAR). Ann Intern Med, In Press. 
Dore, G. J., Altice, F., Litwin, A. H., Dalgard, O., Gane, E. J., Shibolet, O., Luetkemeyer, A., 
Nahass, R., Peng, C. Y., Conway, B., Grebely, J., Howe, A. Y., Gendrano, I. N., 
Chen, E., Huang, H. C., Dutko, F. J., Nickle, D. C., Nguyen, B. Y., Wahl, J., Barr, E., 
Robertson, M. N., Platt, H. L., & Group, C. E. C.-S. S. (2016). Elbasvir-Grazoprevir 
to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A 
Randomized Trial. Ann Intern Med, 165, 625-634. 
Dore, G. J., & Feld, J. J. (2015). Hepatitis C virus therapeutic development: in pursuit of 
"perfectovir". Clin Infect Dis, 60, 1829-1836. 
European Association for Study of, L. (2015). EASL Recommendations on Treatment of 
Hepatitis C 2015. J Hepatol, 63, 199-236. 
European Union, H. C. V. C. (2017). Hepatitis C virus prevalence and level of intervention 
required to achieve the WHO targets for elimination in the European Union by 2030: 
a modelling study. Lancet Gastroenterol Hepatol, 2, 325-336. 
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & 
Sulkowski, M. S. (2017). Oral Direct-Acting Agent Therapy for Hepatitis C Virus 
Infection: A Systematic Review. Ann Intern Med, 166, 637-648. 
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., 
Aguilar, H., Xiong, J., Pilot-Matias, T., DaSilva-Tillmann, B., Larsen, L., Podsadecki, 
T., & Bernstein, B. (2014). Treatment of HCV with ABT-450/r-ombitasvir and 
dasabuvir with ribavirin. N Engl J Med, 370, 1594-1603. 
Fischer, B., & Argento, E. (2012). Prescription opioid related misuse, harms, diversion and 
interventions in Canada: a review. Pain Physician, 15, ES191-203. 
Foucher, J., Reiller, B., Jullien, V., Leal, F., di Cesare, E. S., Merrouche, W., Delile, J. M., & 
de Ledinghen, V. (2009). FibroScan used in street-based outreach for drug users is 
useful for hepatitis C virus screening and management: a prospective study. J Viral 
Hepat, 16, 121-131. 
Gardner, E. M., McLees, M. P., Steiner, J. F., Del Rio, C., & Burman, W. J. (2011). The 
spectrum of engagement in HIV care and its relevance to test-and-treat strategies for 
prevention of HIV infection. Clinical infectious diseases, 52, 793-800. 
Graham, S., Harrod, M. E., Iversen, J., & Simone Hocking, J. (2016). Prevalence of Hepatitis 
C Among Australian Aboriginal and Torres Strait Islander people: A Systematic 
Review and Meta-Analysis. Hepat Mon, 16, e38640. 
Grebely, J., Dalgard, O., Conway, B., Cunningham, E., Bruggmann, P., Hajarizadeh, B., 
Amin, J., Marks, P., Quiene, S., Applegate, T. A., Swan, T., Byrne, J., Lacalamita, 
M., Dunlop, A. J., Bruneau, J., Hellard, M. E., Matthews, G. V., Powis, J., Shaw, D., 
Thurnheer, C. M., Weltman, M., Kronborg, I., Cooper, C., Feld, J. J., Fraser, C., 
Litwin, A., Dillon, J., Read, P., Gane, E., & Dore, G. J. (2017). Efficacy and safety of 
sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent 
injecting drug use: the SIMPLIFY study. J Hepatol, 66, S513. 
Grebely, J., & Dore, G. J. (2011). What is killing people with hepatitis C virus infection? 
Semin Liver Dis, 31, 331-339. 
Grebely, J., Dore, G. J., Zeuzem, S., Aspinall, R. J., Fox, R., Han, L., McNally, J., Osinusi, 
A., Brainard, D. M., Subramanian, G. M., Natha, M., Foster, G. R., Mangia, A., 
Sulkowski, M., & Feld, J. J. (2016). Efficacy and Safety of Sofosbuvir/Velpatasvir in 
25 
 
Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution 
Therapy: Analysis of Phase 3 ASTRAL Trials. Clin Infect Dis. 
Grebely, J., Jacobson, I. M., Kayali, Z., Verna, E. C., Shiffman, M. L., Hyland, R. H., 
Stamm, L. M., Huang, K. C., Brainard, D. M., McHutchison, J. G., Pol, S., Chung, R. 
T., Bernstein, D. E., & Dore, G. J. (2017). SOF/VEL/VOX for 8 or 12 Weeks Is Well 
Tolerated and Results in High SVR12 Rates in Patients Receiving Opioid Substitution 
Therapy. J Hepatol, 66, S513. 
Grebely, J., Lamoury, F. M. J., Hajarizadeh, B., Mowat, Y., Marshall, A. D., Bajis, S., Marks, 
P., Amin, J., Smith, J., Edwards, M., Gorton, C., Ezard, N., Persing, D., Kleman, M., 
Cunningham, P., Catlett, B., Dore, G. J., Applegate, T. L., & Live, R. S. G. (2017). 
Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-
collected and finger-stick capillary whole-blood samples: a cohort study. Lancet 
Gastroenterol Hepatol, 2, 514-520. 
Grebely, J., Mauss, S., Brown, A., Bronowicki, J. P., Puoti, M., Wyles, D., Natha, M., Zhu, 
Y., Yang, J., Kreter, B., Brainard, D. M., Yun, C., Carr, V., & Dore, G. J. (2016). 
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients 
With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: 
Analysis of Phase 3 ION Trials. Clin Infect Dis. 
Grebely, J., Oser, M., Taylor, L. E., & Dore, G. J. (2013). Breaking down the barriers to 
hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: 
action required at the system, provider, and patient levels. J Infect Dis, 207 Suppl 1, 
S19-25. 
Grebely, J., Puoti, M., Wedemeyer, H., Cooper, C. S., Sulkowski, M. S., Foster, G. F., Berg, 
T., Villa, E., Rodriguez-Perez, F., Wyles, D. L., Alami, N. N., Zhang, Z., Dumas, E., 
& Dore, G. J. (2017). Safety and Efficacy of Ombitasvir, Paritaprevir/Ritonavir and 
Dasabuvir With or Without Ribavirin in Chronic Hepati ti s C Pati ents Receiving 
Opioid Substi tuti on Therapy: A Pooled Analysis Across 12 Clinical Trials. J 
Hepatol, 66, S514. 
Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., Byrne, J., 
Dalgard, O., Feld, J. J., Hellard, M., Hickman, M., Kautz, A., Litwin, A., Lloyd, A. 
R., Mauss, S., Prins, M., Swan, T., Schaefer, M., Taylor, L. E., Dore, G. J., & 
International Network for Hepatitis in Substance, U. (2015). Recommendations for 
the management of hepatitis C virus infection among people who inject drugs. Int J 
Drug Policy, 26, 1028-1038. 
Grebely, J., & Tyndall, M. W. (2011). Management of HCV and HIV infections among 
people who inject drugs. Curr Opin HIV AIDS, 6, 501-507. 
Hadland, S. E., DeBeck, K., Kerr, T., Feng, C., Montaner, J. S., & Wood, E. (2014). 
Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of 
misuse in a prospective cohort of street youth. BMJ Open, 4, e005419. 
Hagan, H., Pouget, E. R., Des Jarlais, D. C., & Lelutiu-Weinberger, C. (2008). Meta-
regression of hepatitis C virus infection in relation to time since onset of illicit drug 
injection: the influence of time and place. Am J Epidemiol, 168, 1099-1109. 
Hagedorn, H., Dieperink, E., Dingmann, D., Durfee, J., Ho, S. B., Isenhart, C., Rettmann, N., 
& Willenbring, M. (2007). Integrating hepatitis prevention services into a substance 
use disorder clinic. Journal of Substance Abuse Treatment, 32, 391-398. 
Hajarizadeh, B., Grebely, J., & Dore, G. J. (2013). Epidemiology and natural history of HCV 
infection. Nat Rev Gastroenterol Hepatol, 10, 553-562. 
Hajarizadeh, B., Grebely, J., Matthews, G., Martinello, M., & Dore, G. (2016). Treatment 
uptake for chronic hepatitis C in Australia following universal access to interferon-
26 
 
free treatments. In  Hepatology (Vol. 63, pp. 948A-948A): WILEY-BLACKWELL 
111 RIVER ST, HOBOKEN 07030-5774, NJ USA. 
Harris, M., & Rhodes, T. (2013). Hepatitis C treatment access and uptake for people who 
inject drugs: a review mapping the role of social factors. Harm Reduct J, 10, 7. 
Havens, J. R., Lofwall, M. R., Frost, S. D., Oser, C. B., Leukefeld, C. G., & Crosby, R. A. 
(2013). Individual and network factors associated with prevalent hepatitis C infection 
among rural Appalachian injection drug users. Am J Public Health, 103, e44-52. 
Havens, J. R., Walker, R., & Leukefeld, C. G. (2007). Prevalence of opioid analgesic 
injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend, 87, 
98-102. 
Hellard, M., Rolls, D. A., Sacks-Davis, R., Robins, G., Pattison, P., Higgs, P., Aitken, C., & 
McBryde, E. (2014). The impact of injecting networks on hepatitis C transmission 
and treatment in people who inject drugs. Hepatology, 60, 1861-1870. 
Hellard, M., Sacks-Davis, R., & Gold, J. (2009). Hepatitis C treatment for injection drug 
users: a review of the available evidence. Clin Infect Dis, 49, 561-573. 
Hickman, M., McDonald, T., Judd, A., Nichols, T., Hope, V., Skidmore, S., & Parry, J. V. 
(2008). Increasing the uptake of hepatitis C virus testing among injecting drug users 
in specialist drug treatment and prison settings by using dried blood spots for 
diagnostic testing: a cluster randomized controlled trial. Journal of viral hepatitis, 15, 
250-254. 
Hirsch, A. A., Lawrence, R. H., Kern, E., Falck-Ytter, Y., Shumaker, D. T., & Watts, B. 
(2014). Implementation and evaluation of a multicomponent quality improvement 
intervention to improve efficiency of hepatitis C screening and diagnosis. Jt Comm J 
Qual Patient Saf, 40, 351-357. 
Ho, S. B., Brau, N., Cheung, R., Liu, L., Sanchez, C., Sklar, M., Phelps, T. E., Marcus, S. G., 
Wasil, M. M., Tisi, A., Huynh, L., Robinson, S. K., Gifford, A. L., Asch, S. M., & 
Groessl, E. J. (2015). Integrated care increases treatment and improves outcomes of 
patients with chronic hepatitis C virus infection and psychiatric illness or substance 
abuse. Clinical Gastroenterology and Hepatology, 13, 2005-2014.e2003. 
Iversen, J., Grebely, J., Topp, L., Wand, H., Dore, G., & Maher, L. (2014). Uptake of 
hepatitis C treatment among people who inject drugs attending Needle and Syringe 
Programs in Australia, 1999-2011. J Viral Hepat, 21, 198-207. 
Jordan, A. E., Blackburn, N. A., Des Jarlais, D. C., & Hagan, H. (2017). Past-year prevalence 
of prescription opioid misuse among those 11 to 30years of age in the United States: 
A systematic review and meta-analysis. J Subst Abuse Treat, 77, 31-37. 
Lacey, C., Ellen, S., Devlin, H., Wright, E., & Mijch, A. (2007). Hepatitis C in psychiatry 
inpatients: Testing rates, prevalence and risk behaviours. Australasian Psychiatry, 15, 
315-319. 
Larney, S., Grebely, J., Hickman, M., De Angelis, D., Dore, G. J., & Degenhardt, L. (2015). 
Defining populations and injecting parameters among people who inject drugs: 
Implications for the assessment of hepatitis C treatment programs. Int J Drug Policy, 
26, 950-957. 
Lelutiu-Weinberger, C., Pouget, E. R., Des Jarlais, D. D., Cooper, H. L., Scheinmann, R., 
Stern, R., Strauss, S. M., & Hagan, H. (2009). A meta-analysis of the hepatitis C virus 
distribution in diverse racial/ethnic drug injector groups. Soc Sci Med, 68, 579-590. 
Lima, V. D., Rozada, I., Grebely, J., Hull, M., Lourenco, L., Nosyk, B., Krajden, M., 
Yoshida, E., Wood, E., & Montaner, J. S. (2015). Are Interferon-Free Direct-Acting 
Antivirals for the Treatment of HCV Enough to Control the Epidemic among People 
Who Inject Drugs? PLoS One, 10, e0143836. 
27 
 
Marshall, A. D., Micallef, M., Erratt, A., Telenta, J., Treloar, C., Everingham, H., Jones, S. 
C., Bath, N., How-Chow, D., Byrne, J., Harvey, P., Dunlop, A., Jauncey, M., Read, 
P., Collie, T., Dore, G. J., & Grebely, J. (2015). Liver disease knowledge and 
acceptability of non-invasive liver fibrosis assessment among people who inject drugs 
in the drug and alcohol setting: The LiveRLife Study. Int J Drug Policy, 26, 984-991. 
Marshall, A. D., Nielsen, S., Cunningham, E. B., Aghemo, A., Alho, H., Backmund, M., 
Bruggmann, P., Dalgard, O., Flisiak, R., Foster, G., Gheorghe, L., Goldberg, D., 
Goulis, I., Hickman, M., Hoffmann, P., Jancorienė, L., Jarčuška, P., Kåberg, M., 
Makara, M., Maimets, M., Marinho, R., Matičič, M., Norris, S., Ólafsson, S., 
Øvrehus, A., Pawlotsky, J. M., Pocock, J., Robaeys, G., Roncero, C., Simonova, M., 
Sperl, J., Tait, M., Tolmane, I., Tomaselli, S., van der Valk, M., Vince, A., Dore, G. 
J., Lazarus, J. V., & Grebely, J. (2017). Restrictions for reimbursement of interferon-
free direct acting antiviral therapies for HCV infection in Europe. J Hepatol, 66, S95–
S96. 
Marshall, A. D., Saeed, S., Barrett, L., Cooper, C. L., Treloar, C., Bruneau, J., Feld, J. J., 
Gallagher, L., Klein, M. B., Krajden, M., Shoukry, N. H., Taylor, L. E., Grebely, J., & 
Canadian Network on Hepatitis, C. (2016). Restrictions for reimbursement of direct-
acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive 
study. CMAJ Open, 4, E605-E614. 
Marshall, B. D., Green, T. C., Yedinak, J. L., & Hadland, S. E. (2016). Harm reduction for 
young people who use prescription opioids extra-medically: Obstacles and 
opportunities. Int J Drug Policy, 31, 25-31. 
Martin, N. K., Hickman, M., Hutchinson, S. J., Goldberg, D. J., & Vickerman, P. (2013). 
Combination interventions to prevent HCV transmission among people who inject 
drugs: modeling the impact of antiviral treatment, needle and syringe programs, and 
opiate substitution therapy. Clin Infect Dis, 57 Suppl 2, S39-45. 
Martin, N. K., Vickerman, P., Dore, G. J., Grebely, J., Miners, A., Cairns, J., Foster, G. R., 
Hutchinson, S. J., Goldberg, D. J., Martin, T. C., Ramsay, M., Consortium, S.-H., & 
Hickman, M. (2016). Prioritization of HCV treatment in the direct-acting antiviral era: 
An economic evaluation. J Hepatol, 65, 17-25. 
Martin, N. K., Vickerman, P., Foster, G. R., Hutchinson, S. J., Goldberg, D. J., & Hickman, 
M. (2011). Can antiviral therapy for hepatitis C reduce the prevalence of HCV among 
injecting drug user populations? A modeling analysis of its prevention utility. J 
Hepatol, 54, 1137-1144. 
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, 
G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., & Hickman, M. (2013). Hepatitis C 
virus treatment for prevention among people who inject drugs: Modeling treatment 
scale-up in the age of direct-acting antivirals. Hepatology, 58, 1598-1609. 
Masson, C. L., Delucchi, K. L., McKnight, C., Hettema, J., Khalili, M., Min, A., Jordan, A. 
E., Pepper, N., Hall, J., & Hengl, N. S. (2013). A randomized trial of a hepatitis care 
coordination model in methadone maintenance treatment. American journal of public 
health, 103, e81-e88. 
Merchant, R. C., Baird, J. R., Liu, T., Taylor, L. E., Montague, B. T., & Nirenberg, T. D. 
(2014). Brief intervention to increase emergency department uptake of combined 
rapid human immunodeficiency virus and hepatitis C screening among a drug 
misusing population. Academic Emergency Medicine, 21, 752-767. 
Merchant, R. C., DeLong, A. K., Liu, T., & Baird, J. R. (2015). Factors influencing uptake of 
rapid HIV and hepatitis C screening among drug misusing adult emergency 
department patients: Implications for future HIV/HCV screening interventions. Aids 
and Behavior, 19, 2025-2035. 
28 
 
Miller, C. L., Johnston, C., Spittal, P. M., Li, K., Laliberte, N., Montaner, J. S., & Schechter, 
M. T. (2002). Opportunities for prevention: hepatitis C prevalence and incidence in a 
cohort of young injection drug users. Hepatology, 36, 737-742. 
Moessner, B. K., Jorgensen, T. R., Skamling, M., Vyberg, M., Junker, P., Pedersen, C., & 
Christensen, P. B. (2011). Outreach screening of drug users for cirrhosis with 
transient elastography. Addiction, 106, 970-976. 
Morris, M. D., Shiboski, S., Bruneau, J., Hahn, J. A., Hellard, M., Prins, M., Cox, A. L., 
Dore, G., Grebely, J., Kim, A. Y., Lauer, G. M., Lloyd, A., Rice, T., Shoukry, N., 
Maher, L., Page, K., International Collaboration of Incident, H. I. V., & Cohorts, H. 
C. V. i. I. (2017). Geographic Differences in Temporal Incidence Trends of Hepatitis 
C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. Clin 
Infect Dis, 64, 860-869. 
Moussalli, J., Delaquaize, H., Boubilley, D., Lhomme, J. P., Ponty, J. M., Sabot, D., Kerever, 
A., Valleur, M., & Poynard, T. (2010). Factors to improve the management of 
hepatitis C in drug users: An observational sudy in an addiction centre. 
Gastroenterology Research and Practice, 2010. 
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & 
Degenhardt, L. (2011). Global epidemiology of hepatitis B and hepatitis C in people 
who inject drugs: results of systematic reviews. Lancet, 378, 571-583. 
Ooka, K., Connolly, J. J., & Lim, J. K. (2017). Medicaid Reimbursement for Oral Direct 
Antiviral Agents for the Treatment of Chronic Hepatitis C. Am J Gastroenterol, 112, 
828-832. 
Page, K., Morris, M. D., Hahn, J. A., Maher, L., & Prins, M. (2013). Injection drug use and 
hepatitis C virus infection in young adult injectors: using evidence to inform 
comprehensive prevention. Clin Infect Dis, 57 Suppl 2, S32-38. 
Puoti, M., Cooper, C., Sulkowski, M. S., Foster, G. R., Berg, T., Villa, E., Rodriguez-Perez, 
F., Rustgi, V., Wyles, D. L., King, M., McGovern, B. H., & Wedemeyer, H. (2014). 
ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 
1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis 
of Efficacy and Safety in Phase 2 and Phase 3 Trials. Hepatology, 60, 1135a-1136a. 
Radley, A., Melville, K., Tait, J., Stephens, B., Evans, J. M., & Dillon, J. F. (2017). A quasi-
experimental evaluation of dried blood spot testing through community pharmacies in 
the Tayside region of Scotland. Frontline Gastroenterology, flgastro-2016-100776. 
Rosenberg, S. D., Goldberg, R. W., Dixon, L. B., Wolford, G. L., Slade, E. P., Himelhoch, S., 
Gallucci, G., Potts, W., Tapscott, S., & Welsh, C. J. (2010). Assessing the STIRR 
model of best practices for blood-borne infections of clients with severe mental 
illness. Psychiatric Services, 61, 885-891. 
Roux, P., Castro, D. R., Ndiaye, K., Debrus, M., Protopopescu, C., Le Gall, J. M., Haas, A., 
Mora, M., Spire, B., Suzan-Monti, M., & Carrieri, P. (2016). Increased uptake of 
HCV testing through a community-based educational intervention in difficult-to-reach 
people who inject drugs: Results from the ANRS-AERLI study. PloS one, 11. 
Roy, E., Boudreau, J. F., & Boivin, J. F. (2009). Hepatitis C virus incidence among young 
street-involved IDUs in relation to injection experience. Drug Alcohol Depend, 102, 
158-161. 
Scott, N., McBryde, E. S., Thompson, A., Doyle, J. S., & Hellard, M. E. (2016). Treatment 
scale-up to achieve global HCV incidence and mortality elimination targets: a cost-
effectiveness model. Gut. 
Stanaway, J. D., Flaxman, A. D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., Abu-
Raddad, L. J., Assadi, R., Bhala, N., Cowie, B., Forouzanfour, M. H., Groeger, J., 
Mohd Hanafiah, K., Jacobsen, K. H., James, S. L., MacLachlan, J., Malekzadeh, R., 
29 
 
Martin, N. K., Mokdad, A. A., Mokdad, A. H., Murray, C. J., Plass, D., Rana, S., 
Rein, D. B., Richardus, J. H., Sanabria, J., Saylan, M., Shahraz, S., So, S., Vlassov, V. 
V., Weiderpass, E., Wiersma, S. T., Younis, M., Yu, C., El Sayed Zaki, M., & Cooke, 
G. S. (2016). The global burden of viral hepatitis from 1990 to 2013: findings from 
the Global Burden of Disease Study 2013. Lancet, 388, 1081-1088. 
Strike, C., Millson, M., Hopkins, S., & Smith, C. (2013). What is low threshold methadone 
maintenance treatment? Int J Drug Policy, 24, e51-56. 
Swan, D., Long, J., Carr, O., Flanagan, J., Irish, H., Keating, S., Keaveney, M., Lambert, J., 
McCormick, P. A., McKiernan, S., Moloney, J., Perry, N., & Cullen, W. (2010). 
Barriers to and facilitators of hepatitis C testing, management, and treatment among 
current and former injecting drug users: a qualitative exploration. AIDS Patient Care 
STDS, 24, 753-762. 
Tait, J. M., McIntyre, P. G., McLeod, S., Nathwani, D., & Dillon, J. F. (2010). The impact of 
a managed care network on attendance, follow-up and treatment at a hepatitis C 
specialist centre. Journal of viral hepatitis, 17, 698-704. 
Treloar, C., Hull, P., Bryant, J., Hopwood, M., Grebely, J., & Lavis, Y. (2011). Factors 
associated with hepatitis C knowledge among a sample of treatment naive people who 
inject drugs. Drug Alcohol Depend, 116, 52-56. 
Treloar, C., Hull, P., Dore, G. J., & Grebely, J. (2012). Knowledge and barriers associated 
with assessment and treatment for hepatitis C virus infection among people who inject 
drugs. Drug Alcohol Rev, 31, 918-924. 
Treloar, C., Rance, J., Bath, N., Everingham, H., Micallef, M., Day, C., Hazelwood, S., 
Grebely, J., & Dore, G. J. (2015). Evaluation of two community-controlled peer 
support services for assessment and treatment of hepatitis C virus infection in opioid 
substitution treatment clinics: The ETHOS study, Australia. Int J Drug Policy, 26, 
992-998. 
United Nations Office on Drugs and Crime, I. N. o. P. W. U. D., Joint United Nations 
Programme on HIV/AIDS, United Nations Development Programme, United Nations 
Population Fund, World Health Organization, United States Agency for International 
Development. . Implementing comprehensive HIV and HCV programmes with people 
who inject drugs: practical guidance for collaborative interventions. .  from 
http://www.unodc.org/documents/hiv-
aids/publications/Implementing_Comprehensive_HIV_and_HCV_Programmes_with_
People_Who_Inject_Drugs_PRACTICAL_GUIDANCE_FOR_COLLABORATIVE_
INTERVENTIONS.pdf. 
van der Meer, A. J., Wedemeyer, H., Feld, J. J., Dufour, J. F., Zeuzem, S., Hansen, B. E., & 
Janssen, H. L. (2014). Life expectancy in patients with chronic HCV infection and 
cirrhosis compared with a general population. JAMA, 312, 1927-1928. 
WHO. (2014). Guidelines for the screening, care and treatment of persons with hepatitis C 
infection. In W. H. Organization (Ed.). Geneva, Switzerland. 
WHO. Global health sector strategy on viral hepatitis 2016-2021. Retrieved June 5, 2017  
from http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-
eng.pdf?ua=1. 
WHO. (2017b). Global Hepatitis Report 2017. . In W. H. Organization (Ed.). Geneva: World 
Health Organization. 
Wiessing, L., Ferri, M., Grady, B., Kantzanou, M., Sperle, I., Cullen, K. J., group, E. D., 
Hatzakis, A., Prins, M., Vickerman, P., Lazarus, J. V., Hope, V. D., & Mathei, C. 
(2014). Hepatitis C virus infection epidemiology among people who inject drugs in 
Europe: a systematic review of data for scaling up treatment and prevention. PLoS 
One, 9, e103345. 
30 
 
Wolfe, D., Luhmann, N., Harris, M., Momenghalibaf, A., Albers, E., Byrne, J., & Swan, T. 
(2015). Human rights and access to hepatitis C treatment for people who inject drugs. 
Int J Drug Policy, 26, 1072-1080. 
Yehia, B. R., Schranz, A. J., Umscheid, C. A., & Lo Re, V., 3rd. (2014). The treatment 
cascade for chronic hepatitis C virus infection in the United States: a systematic 
review and meta-analysis. PLoS One, 9, e101554. 
Younossi, Z., & Henry, L. (2015). Systematic review: patient-reported outcomes in chronic 
hepatitis C--the impact of liver disease and new treatment regimens. Aliment 
Pharmacol Ther, 41, 497-520. 
Zeuzem, S., Ghalib, R., Reddy, K. R., Pockros, P. J., Ben Ari, Z., Zhao, Y., Brown, D. D., 
Wan, S., DiNubile, M. J., Nguyen, B. Y., Robertson, M. N., Wahl, J., Barr, E., & 
Butterton, J. R. (2015). Grazoprevir-Elbasvir Combination Therapy for Treatment-
Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 
1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med, 163, 1-13. 
Zibbell, J. E., Hart-Malloy, R., Barry, J., Fan, L., & Flanigan, C. (2014). Risk factors for 
HCV infection among young adults in rural New York who inject prescription opioid 
analgesics. Am J Public Health, 104, 2226-2232. 
 
 
 
 
